Paradigm Biopharmaceuticals Limited (ASX:PAR)

Australia flag Australia · Delayed Price · Currency is AUD
0.255
0.00 (0.00%)
At close: Mar 6, 2026
-44.57%
Market Cap 112.01M
Revenue (ttm) 8.45K
Net Income (ttm) -36.09M
Shares Out 439.25M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 355,045
Average Volume 1,043,471
Open 0.250
Previous Close 0.255
Day's Range 0.250 - 0.260
52-Week Range 0.240 - 0.492
Beta 0.18
RSI 32.17
Earnings Date Feb 25, 2026

About ASX:PAR

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol PAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.